New program aims to slash deadly blood clots in hospital patients
NCT ID NCT04211181
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This study tests whether a comprehensive quality improvement program can increase the use of blood clot prevention methods in hospitalized patients across China. The program includes clinical guidelines, care protocols, and a mobile app for risk assessment. Researchers will compare hospitals using the program to those providing standard care, measuring how many at-risk patients receive proper prevention and how many develop clots within 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100029, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
quality improvement program (guidelines, protocols, mobile app)
What this could lead to
If successful, this could establish a practical, scalable way to prevent dangerous blood clots in hospitalized patients, reducing deaths and complications.
What could go wrong
This is a cluster-randomized trial testing a system-level intervention, not a new drug. Success depends on hospital compliance, and results may not apply outside China.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.